Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia

被引:64
|
作者
Gigliotti, F [1 ]
Haidaris, CG
Wright, TW
Harmsen, AG
机构
[1] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA
[3] Trudeau Inst Inc, Saranac Lake, NY 12983 USA
关键词
D O I
10.1128/IAI.70.3.1069-1074.2002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Passive antibody immunoprophylaxis is one method used to protect patients against infection if they are unable to mount an adequate active immune response. Topical application of antibody may be effective against infections at mucosal sites. Using a SCID mouse model of Pneumocystis carinii pneumonia, we were able to demonstrate protection against an airborne challenge with P. carinii by intranasal administration of antibody. Immunoglobulin M (IgM) monoclonal antibodies to an epitope shared by mouse and human P. carinii organisms reduced organism numbers by more than 99% under the conditions described. An IgG1 switch variant of one of the IgM monoclonal antibodies was also protective. These experiments provide a model for exploring the utility of this approach in protecting at-risk patients from infection with A carinii.
引用
收藏
页码:1069 / 1074
页数:6
相关论文
共 50 条
  • [1] PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA
    GABIN, SJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (13): : 1779 - 1779
  • [2] Withdrawal of prophylaxis against Pneumocystis carinii pneumonia
    Feinberg, J
    LANCET, 1999, 353 (9161): : 1287 - 1287
  • [3] Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
    Le Moal, G
    Breux, JP
    Roblot, F
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (21): : 1639 - 1640
  • [4] PRIMARY PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA
    TARABEY, R
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (20): : 1499 - 1499
  • [5] RECOMMENDATIONS FOR PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA
    VEUGELERS, PJ
    VEENSTRA, J
    COUTINHO, RA
    VANGRIENSVEN, GJP
    LANCET, 1993, 341 (8847): : 758 - 758
  • [6] ATOVAQUONE AS PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA
    FISHER, MJ
    GAZZARD, BG
    HAWKINS, DA
    NELSON, MR
    JOURNAL OF INFECTION, 1994, 28 (01) : 103 - 104
  • [7] Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia
    Wells, J
    Haidaris, CG
    Wright, TW
    Gigliotti, F
    INFECTION AND IMMUNITY, 2006, 74 (01) : 390 - 393
  • [8] USE OF FLUOROQUINOLONES FOR PROPHYLAXIS OF MURINE PNEUMOCYSTIS-CARINII PNEUMONIA
    BRUNPASCAUD, M
    FAY, M
    ZHONG, M
    BAUCHET, J
    DUXGUYOT, A
    POCIDALO, JJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (02) : 470 - 472
  • [9] Discontinuing prophylaxis against Pneumocystis carinii pneumonia.: Reply
    Lundgren, J
    Reiss, P
    Ledergerber, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (21): : 1640 - 1641
  • [10] PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA IN CHILDREN WITH HIV
    RAPHAEL, SA
    LISCHNER, HW
    GREGONIS, SW
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (08): : 1078 - 1079